Previous 10 | Next 10 |
2023-07-26 07:00:00 ET Summary Baron Health Care Fund invests in companies engaged in the research, development, production, sale, delivery, or distribution of products and services related to the healthcare industry. In the quarter ended June 30, 2023, Baron Health Care Fund adva...
Shares of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) traded at a new 52-week high today and are currently trading at $23.63. So far today, approximately 342.95k shares have been exchanged, as compared to an average 30-day volume of 623.23k shares. Rocket Pharmaceuticals, Inc., together with ...
2023-06-08 08:38:34 ET Rocket Pharmaceuticals ( NASDAQ: RCKT ) announced Thursday that the FDA granted Fast Track and Orphan Drug designations for its gene therapy candidate RP-A601 as a treatment for the rare heart disorder, plakophilin-2 related arrhythmogenic cardiomyopathy (PKP2...
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track and Orph...
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) ...
2023-05-23 07:28:02 ET The U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to Rocket Pharmaceuticals' ( NASDAQ: RCKT ) lentiviral-based gene therapy RP-L301 to treat Pyruvate Kinase Deficiency (PKD) PKD is a rare b...
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medici...
2023-05-19 07:20:07 ET Rocket Pharmaceuticals ( NASDAQ: RCKT ) reported data from several gene therapy programs at the 26th Annual Meeting of the American Society of Gene and Cell Therapy in Los Angeles. Pyruvate Kinase Deficiency (PKD) The company reported data from two...
Robust and sustained efficacy in both adult PKD patients up to 30 months post-RP-L301; first pediatric patient results suggest efficacy similar to adult cohort with initial greater than five-point increase in hemoglobin Sustained genetic correction observed in eight of 12 evaluable Fancon...
2023-05-11 14:34:03 ET Summary Today, we peek back in on Rocket Pharmaceuticals, Inc. for the first time in 2023. The company is seeing some momentum from positive trial developments and new-found enthusiasm from the analyst community so far here in May. An investment analysis...
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
11.34%Change Percent:
Rocket Pharmaceuticals Inc. Company Name:
RCKT Stock Symbol:
NASDAQ Market:
Rocket Pharmaceuticals Inc. Website:
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet needs, today announced a regulatory update for KRESLADI™ (marnetegragene autotemcel; marne-cel), a le...
2024-06-02 14:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the European Commission (EC), based on a positive opinion issued by the Committ...